Mr. Fernández Sousa-Faro has been a Professor of Biochemistry at the Complutense University of Madrid and the University of Santiago de Compostela, he obtained an MBA from the IESE Business School in Madrid. Dr. Fernández Sousa-Faro has over 90 scientific articles and patents in the field of biochemistry, drug discovery and molecular biology. With more than 25 years of experience in the pharmaceutical industry, he has held positions within the executive management of ICI-Farma, Antibióticos, Zeltia and Pharma Mar.
He was a member of the Board of Directors of Antibiotics, Penibérica, Biolys, ICI-Farma, Pescanova, Transfesa, Cooper–Zeltia, ICI-Zeltia and Banco Guipuzcoano. He founded Pharma Mar in 1986 and is currently the Chairman of the Board of Directors and Executive President of Pharma Mar.
With 30 years experience in the pharmaceutical industry and a Degree in Business Administration and MBA from the University of Barcelona, Luis Mora began his career as the Financial Controller for Zambon, S.A. and Pharmazam, S.A. in Barcelona and later as Head of Finance for Zambón Portugal. From 1995-2000 he served as Financial Controller with the Antibióticos Group (Montedison), and as Board Member of Vitatene, in Milan, Italy.
He joined PharmaMar in 2000 as Chief Financial Officer and was appointed Managing Director in 2008.
With almost 30 years of experience in the pharmaceutical industry, Ms. de Francia started working at Pharma Mar in 1988 where she held different positions within the finance department. In 2000, she was appointed Chief Financial Officer. She received an undergraduate degree in law and a master’s degree in business administration from Comillas Pontifical University.
He is currently General Counsel and Secretary of the Board of Directors of Pharma Mar, a position he has held since July 2019. Since joining Zeltia, S.A. in January 2013, and later in Pharma Mar, he has been Senior Legal Counsel of the Legal Department of the Group. Previously, he was a Senior Associate of the Corporate and M&A Department of Ramón y Cajal Abogados, as well as an Associate of the corporate department of other national and international law firms.
He has a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Corporate Law from IE Business School.
Sandra Llamera joined PharmaMar as Global Compliance Head in April 2020, bringing with her 18 years of experience in the pharmaceutical industry.
Since 2018, she has been a member of the Board of Directors of the Institute of Compliance Officers (IOC, by its Spanish acronym), transmitting ethical values at the corporate level and promoting the compliance profession. She has combined this role while working at Teva, as Director of Compliance for Spain and Portugal. During this period, she implemented the compliance program at the factory and at the logistics center in Spain, led the adaptation of the Company in Spain and Portugal to the new European Data Protection Regulation (GDPR), and actively participated in the design and implementation of the Global Compliance program as a result of the monitoring imposed by the US Department of Justice (DOJ).
Sandra began her career at Pfizer, serving in various departments, including the legal and the compliance department, for 12 years. She advised on Anti-corruption, FCPA regulations, monitoring of clinical studies (NIS), Drug Promotion and Promotional Activities, Competition, Third Party Due Diligence Programs, Policies and Procedures, internal and external audits, among others, implementing various control tools and reviewing activities of the different areas within the Company.
She has a degree in Law from the San Paulo CEU University. She has also been a speaker at courses and conferences on Compliance, Promotion of Medicines and Data Protection for bodies such as the Word Compliance Association, the Spanish Association of Pharmacists in Industry (AEFI, by its Spanish acronym) and the Madrid Bar Association (ICAM, by its Spanish acronym).
Mr. Moreno holds the position of Director of Capital Markets and Investor Relations at Pharma Mar, a position he has also held at Zeltia since 2009. From 2002 until 2009, he was the co-founder and managing partner of the independent financial group Solventis. He was previously head of equity sales at Banco Espirito Santo Investment for three years after holding this same post for non-resident clients at Benito y Monjardín SVB. He started his career in capital markets in 1994 working in the research and marketing department of the Spanish Futures and Options Exchange (MEFF RF), developing financial derivatives.
Mr. Moreno received an undergraduate degree in Management and Business Administration from the University of Hertfordshire and a degree in Business Administration from the University of Barcelona. He also completed a management development program (PDG) from IESE and he holds a C.A.I.A. (Chartered Alternative Investment Analyst). He has been invited to teach courses on financial derivative products for Masters courses in financial markets offered by the University of Barcelona, as well as other related courses at the Abat Oliba CEU University, the Center for Financial Studies and MEFF.
José Luis received his Master’s degree in Biochemistry from the Complutense University of Madrid. He has 32 years experience in Quality related issues, 28 of them in different management positions within the pharmaceutical industry (Bristol-Myers, DSM Deretil and Justesa Imagen S.A).
He also has worked at the Spanish National Accreditation Body (ENAC) and as a Quality consultant. He joined Pharma Mar in 2004 as the Director of Pharma Mar’s Quality Unit.
Ms. Sanz is currently director of the business area of the Legal Department of Pharma Mar, a position she holds since July 2019. Ms. Sanz joined Pharma Mar in 2007 as Legal Advisor and in 2015 she was appointed as Vicesecretary of the Boards of Director of Pharma Mar. Previously, she was an Associate of Elzaburu law firm.
Ms. Sanz has a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Intellectual Property (Magister Lvcentinvs) from University of Alicante.
She joined PharmaMar in 2005 and has been Group Corporate Affairs Director since 2020. She was previously Director of Market Research and has also held senior positions in two group companies. She was General Manager (2015-2018) and member of the Board (2014-2018) on behalf of PharmaMar of Xylazel, a Consumer Chemicals company that belonged to the holding until its sale in 2018. Previously, between 2006 and 2014, she served as General Manager of Noscira S.A., another biotechnology company in the group dedicated to R&D of innovative treatments for neurodegenerative diseases, which she joined in 2005 as Quality Assurance Manager.
In addition, she is a member of the Board representing PharmaMar in Sylentis and an independent member of the Board of the biotechnology company Biocross.
During a previous period (2001-2005), she was Manager and Technical Director of Qualysite Consultores S.L., a company that she founded together with other partners. Prior to this period, she worked in a CRO (Contract Research Organisation), Cibest (currently an international SGS group), where she held various positions within the clinical research department (1997-2001).
She holds a PhD in Pharmacy from the Universidad Complutense de Madrid and a Management Development program at IESE business school.
She belongs to the Spanish Association of Pharmaceutical Medicine (AMIFE), of which she was president from 2013 to 2015, and for the last 20 years she has been a member of the teaching committee of the Master Course in Clinical Trials Monitoring at the Madrid Professional Association of Pharmacists.
With a Master’s in Financial Management from ESIC, he joined the Pharma Mar Group’s Finance team in May 1989. Since November 2011, he has been in charge of the Group’s Internal Audit department, supervising the internal control system for financial reporting. He was previously Chief Accountant at Zeltia (June 2002–Nov. 2011) and at Pharma Mar (Nov. 1994-June 2002), supporting the Group’s other subsidiaries.